EMUC 2025
EMUC 2025
This session features a distinguished panel - Prof. Dr. Christian Schwentner, Prof. Dr. Athanasios Papatsoris and Prof. Gert Attard - who examine how PSA response guides optimal care in mHSPC and highlights strategies to improve outcomes in HRR-mutant disease.
Watch the session on the ecancer platform.
Friday 14 November 2025 | Prague, Czech Republic
.png?width=1208&height=1016&format=webp&quality=50)
About this Session
‘Driving optimal patient outcomes with personalised strategies in mHSPC’
Leading experts provide an in-depth look at how PSA response guides effective management of mHSPC and share approaches to enhance outcomes in HRR-mutated disease
Learning Outcomes
- Management strategies and clinical considerations for patients with mHSPC
- The role and impact of genetic testing in guiding treatment decisions and improving patient outcomes
Hear from the Experts
Prof. Dr. Christian Schwentner
Prof. Dr. Christian Schwentner discusses new research on mHSPC treatment, the role of biomarkers, and key barriers to better prostate cancer care.
Prof. Dr. Athanasios Papatsoris
Prof. Dr. Athanasios (Thanos) Papatsoris discusses the need for better patient stratification and evidence-based, optimised treatment for a range of patients with mHSPC.
Prof. Gert Attard
Prof. Gert Attard explores how early genetic testing and new therapies are transforming prostate cancer care.
Past Events
If you registered for a previous session but were unable to attend, you can log in to access recorded sessions and request materials. Please note that for some recordings and materials, the content may not be available in your country.
Patient and oncologist conversations on the impact of PSA and the importance of psychosexual support
Listen as patient Tony Collier, discusses with Prof. Alison Birtle some of the challenges of living with prostate cancer including the impact of treatment and the importance of open conversations to support sexual health, intimacy, and overall quality of life.
Best practice in precision medicine for prostate cancer - filmed at ESMO 2025
Dr. Elena Castro, Dr. Pasquale Rescigno, Prof. Gert Attard and Prof. Axel Heidenreich discuss how personalised approaches, genomic testing, and targeted therapies are transforming prostate cancer care and improving patient outcomes.
Johnson & Johnson’s Young Experts in Science (YES) Meeting
Our annual meeting – for those earlier in their career specialisation in prostate cancer – focuses on networking, interactive scientific discussions, and enhancing specific skills to improve patient care across the EMEA region by best practice sharing.
| ⓘ The recorded content may not be available in your country. To request access to recordings and session materials, please contact our team. |
Register with J&J Medical Cloud to access our full education library, including recordings, slides, and new session announcements.
Stay in Touch
Contact us
To report an Adverse Event (medication side effect) or a Product Quality Complaint (an issue with one of our products), please select the appropriate link from the Contact dropdown menu. To submit a medical information request, choose the Medical Information page.
Abbreviations
HRR, homologous recombinant repair; mHSPC, metastatic hormone-sensitive prostate cancer; PSA, protein specific antigen.
CP-554492 - December 2025
Janssen Pharmaceutica NV